Size | Price | Stock | Qty |
---|---|---|---|
1g |
|
||
2g |
|
||
5g |
|
||
10g |
|
||
25g |
|
||
50g |
|
||
100g |
|
||
Other Sizes |
|
Purity: ≥98%
Piroxicam (formerly BAXO; CP16171; CP-16171; Feldene; Pyroxycam; Roxicam), an approved non-steroidal anti-inflammatory drug (NSAID), is a potent and non-selective COX inhibitor with potential anti-inflammatory activity. It was approved for the treatment of rheumatoid and osteoarthritis.
ln Vitro |
CP-16171, piroxicam, is a non-steroidal anti-inflammatory medication that inhibits COX. Its IC50 values for human monocyte COX-1 and COX-2 are 47 and 25 μM, respectively[1]. Piroxicam (CP-16171) (167, 333, 500 μM) reduces the T24 and 5637 cell populations. When coupled with 0.05 μM carboplatin, piroxicam (CP-16171) (500 μM) dramatically lowers the viability of T24 and 5637 cells as well. Additionally, the combination prevents booth cells from expressing Ki-67[3].
|
||
---|---|---|---|
ln Vivo |
In 12 out of 18 dogs, piroxicam (CP-16171) (0.3 mg/kg qd 24-h po) lowers the volume of the tumor. This action is caused by apoptosis induction and a decrease in the concentration of basic fibroblast growth factor in the urine[2].
|
||
Animal Protocol |
|
||
References |
[1]. Kato M, et al. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs: investigation using human peripheral monocytes. J Pharm Pharmacol. 2001 Dec;53(12):1679-85.
[2]. Mohammed SI, et al. Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Cancer Res. 2002 Jan 15;62(2):356-8. [3]. Silva J, et al. Synergistic Effect of Carboplatin and Piroxicam on Two Bladder Cancer Cell Lines. Anticancer Res. 2017 Apr;37(4):1737-1745 |
Molecular Formula |
C15H13N3O4S
|
|
---|---|---|
Molecular Weight |
331.35
|
|
CAS # |
36322-90-4
|
|
Related CAS # |
Piroxicam-d3;942047-64-5;Piroxicam-d4
|
|
SMILES |
S1(C2=C([H])C([H])=C([H])C([H])=C2C(=C(C(N([H])C2=C([H])C([H])=C([H])C([H])=N2)=O)N1C([H])([H])[H])O[H])(=O)=O
|
|
Synonyms |
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.54 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.54 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.54 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.0180 mL | 15.0898 mL | 30.1796 mL | |
5 mM | 0.6036 mL | 3.0180 mL | 6.0359 mL | |
10 mM | 0.3018 mL | 1.5090 mL | 3.0180 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.